Preclinical evaluation of antisense bcl‐2 as a chemosensitizer for patients with gastric carcinoma
R Kim, M Emi, K Tanabe, T Toge - … International Journal of the …, 2004 - Wiley Online Library
… , we evaluated the preclinical effect of AS bcl-2 on chemotherapy for patients with gastric …
Thus, our preclinical evaluation of AS Bcl-2 suggests that, in targeting therapy through …
Thus, our preclinical evaluation of AS Bcl-2 suggests that, in targeting therapy through …
Therapeutic potential of antisense Bcl‐2 as a chemosensitizer for cancer therapy
R Kim, M Emi, K Tanabe, T Toge - … International Journal of the …, 2004 - Wiley Online Library
… for patients with other malignancies. Here, the authors review the current clinical and
preclinical evaluations of AS Bcl-2 and discuss its potential to act as a chemosensitizer and to …
preclinical evaluations of AS Bcl-2 and discuss its potential to act as a chemosensitizer and to …
[HTML][HTML] Modulators of multidrug resistance: preclinical studies
JM Ford - Hematology/oncology clinics of North America, 1995 - Elsevier
… The mechanism of activity of these pharmacologic agents, termed chemosensitizers, … models
for the discovery and preclinical evaluation of new chemosensitizers, reviews those agents …
for the discovery and preclinical evaluation of new chemosensitizers, reviews those agents …
[HTML][HTML] Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
… We looked for all clinical or pre-clinical studies related … chemosensitizer depending on
MGMT status stay debated [40, 56–58]even if some phase II-III clinical trials recruits only patients …
MGMT status stay debated [40, 56–58]even if some phase II-III clinical trials recruits only patients …
Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy?
… In this commentary/review, we focus on the relatively limited number of studies in the
literature where chloroquine has been tested in combination with chemotherapy or radiation in …
literature where chloroquine has been tested in combination with chemotherapy or radiation in …
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer
MA Villalona-Calero, MG Wientjes, GA Otterson… - Clinical cancer …, 2003 - AACR
… Purpose: Our preclinical studies have shown that acidic and basic fibroblastic growth factors
confer broad spectrum chemoresistance and that low concentrations (10–50 μm) of suramin…
confer broad spectrum chemoresistance and that low concentrations (10–50 μm) of suramin…
[HTML][HTML] Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed
S Ferrari, F Perut, F Fagioli, A Brach Del Prever… - Journal of translational …, 2013 - Springer
… Patients had to receive ESOM the two days before chemotherapy because preclinical studies
… , that is the minimal effective dose calculated on the basis of the preclinical studies [3, 4]. In …
… , that is the minimal effective dose calculated on the basis of the preclinical studies [3, 4]. In …
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
MA Batey, Y Zhao, S Kyle, C Richardson, A Slade… - Molecular cancer …, 2013 - AACR
… daily resulted in the greatest chemosensitization with a 3-fold … previously observed with
chemosensitization studies (22) … only 4 hours completely abolished chemosensitization. As ATM …
chemosensitization studies (22) … only 4 hours completely abolished chemosensitization. As ATM …
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development
D Chen, SH Song, MG Wientjes, TK Yeh, L Zhao… - Pharmaceutical …, 2006 - Springer
… The present study identified and validated a dosing nomogram and schedule to deliver low
and nontoxic suramin concentrations that produce chemosensitization in preclinical models. …
and nontoxic suramin concentrations that produce chemosensitization in preclinical models. …
Preclinical chemosensitization by PARP inhibitors
DR Shalinsky, CK Donawho, G Los… - PARP Inhibitors for Cancer …, 2015 - Springer
… Table 9.2 AbbVie data summarizing veliparib preclinical studies, monotherapy and …
produced by PARPi used as chemosensitiser in patients with advanced malignancies exposed to …
produced by PARPi used as chemosensitiser in patients with advanced malignancies exposed to …
相关搜索
- patients with gastric carcinoma preclinical evaluation
- noncytotoxic suramin chemosensitizer in patients
- low dose suramin chemosensitizer in patients
- bcl 2 chemosensitizer for patients
- models of human cancer preclinical evaluation
- chemosensitization and radiosensitization preclinical data
- antisense bcl chemosensitizer for patients
- therapeutic potential chemosensitizer for patients
- phase ii study chemosensitizer in patients
- atm inhibitor preclinical evaluation
- cell lung cancer chemosensitizer in patients